Ozette, a Fred Hutch spinout incubated at AI2, raises $6M seed to scale AI immune-monitoring platform

Ozette, a Seattle biotech spun out of Fred Hutch and incubated at AI2, raised a $6 million seed round to scale its eight-person team and commercialize an AI-driven Immune Monitoring Platform that analyzes high-dimensional single-cell protein data, initially focused on cancer. The founders say the platform automates analysis of billions-to-trillions of protein-expression combinations and increases usable information from roughly 10% to 100% of study data.

MMatt McIlwain OOren Etzioni AAllen Institute for AI